image description

Tag: Albert T. Roy

End of Year Message from Lupus Research Alliance President & CEO Albert T. Roy

 2025 has been an extraordinary year of momentum at the Lupus Research Alliance and clinical affiliate Lupus Therapeutics. Hear from Lupus Research Alliance President & CEO Albert T. Roy about how – thanks to your generous support – we continue to advance innovative research, getting us closer to a world free of lupus.    From funded […] Read More

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025

  4 original posters to be presented on cell therapy, patient-reported outcomes, innovative recruitment strategies, and clinical trial retention in lupus  30+ presentations, posters, and discussions are currently supported by the Lupus Research Alliance or Lupus Therapeutics  45+ abstracts involve Lupus Clinical Investigators Network (LuCIN) or previously funded Lupus Research Alliance investigators – including 2 […] Read More

Welcome to “The Lupus Beacon” — from President & CEO Albert T. Roy  

Albert T. Roy, President and CEO of the Lupus Research Alliance, outlines the latest launch of the organization’s new monthly e-newsletter, The Lupus Beacon.    There is much exciting progress to share, and this newsletter is the place to stay informed. Each edition will compile the latest news from our funded research, advances in the […] Read More

Letter from LRA President & CEO Albert T. Roy

Dear Friends, Lupus Awareness Month officially starts today, and with a growing coalition of people like you passionately working together for a world without lupus, never has there been a time for more hope and opportunities for your involvement. Our theme for the month – “Striving for a World Free of Lupus” – aims to […] Read More

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY clinical trial showing benefits of Gazyva® (obinutuzumab) in treating people with active lupus nephritis (inflammation of the kidney associated with lupus). In development as a potential treatment for lupus nephritis, Gazyva is approved in […] Read More

ManyOne ARE Making the Difference

May 1, 2023 Last year, the Lupus Research Alliance launched our ManyOne Can campaign during Lupus Awareness Month to offer opportunities to get involved in our efforts to transform lives of people with lupus. This Lupus Awareness Month, we celebrate the great successes that are already being achieved and exciting ventures coming up that involve […] Read More

Lupus Therapeutics Shifting the Paradigm

The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by becoming the first and only lupus organization to conduct its own clinical trials. How did we achieve what once seemed unobtainable? We created Lupus Therapeutics (an LRA affiliated organization) and since the program started in 2017, […] Read More

Albert T. Roy, Executive Director Lupus Therapeutics, LLC

I’m writing this blog because the Lupus Research Alliance, and its affiliate, Lupus Therapeutics is determined to drive discovery and development of new treatments for lupus! I am proud to serve as Executive Director of Lupus Therapeutics, which serves as fiscal and administrative agent of the Lupus Clinical Investigators Network (LuCIN), a network of 57 […] Read More